X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
ACER-801 (osanetant) is an investigational, novel, non-hormonal, neurokinin 3 receptor (NK3R) antagonist currently being evaluated as a potential treatment option for men with adenocarcinoma of the prostate.
Lead Product(s): Osanetant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: ACER-801
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2023
Details:
ACER-801 (osanetant) is an investigational, novel, non-hormonal, neurokinin 3 receptor (NK3R) antagonist currently being evaluated as a potential treatment option for men with adenocarcinoma of the prostate.
Lead Product(s): Osanetant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: ACER-801
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
ACER-801 (osanetant) is an investigational, novel, non-hormonal, neurokinin 3 receptor (NK3R) antagonist currently being evaluated as a potential treatment option for men with adenocarcinoma of the prostate.
Lead Product(s): Osanetant
Therapeutic Area: Oncology Product Name: ACER-801
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
Funding from the grant will allow to investigate the potential of ACER-801 (osanetant) to reduce the frequency and severity of acute stress disorder and post-traumatic stress disorder (PTSD).
Lead Product(s): Osanetant
Therapeutic Area: Psychiatry/Psychology Product Name: ACER-801
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Department of Defense
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Funding October 06, 2022
Details:
By administering the potent and specific NK3R antagonist, ACER-801 (osanetant), Tac2 genes were able to block fear memory consolidation shortly after exposure to a trauma, potentially providing a novel therapeutic approach for disorders with altered fear learning such as PTSD.
Lead Product(s): Osanetant
Therapeutic Area: Psychiatry/Psychology Product Name: ACER-801
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
Results from the trial could provide proof of concept data in post-menopausal women and could inform ACER-801(osanetant) dosing and a development path forward in patients with induced Vasomotor Symptoms (iVMS).
Lead Product(s): Osanetant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: ACER-801
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
